Inozyme Pharma
INZY
INZY was delisted on the 30th of June, 2025.
97 hedge funds and large institutions have $42.5M invested in Inozyme Pharma in 2025 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 30 increasing their positions, 29 reducing their positions, and 20 closing their positions.
1,200% more call options, than puts
Call options by funds: $13K | Put options by funds: $1K
3% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 29
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
8% less funds holding
Funds holding: 105 → 97 (-8)
8.83% less ownership
Funds ownership: 81.56% → 72.73% (-8.8%)
40% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 20
71% less capital invested
Capital invested by funds: $145M → $42.5M (-$103M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PFCS
Pale Fire Capital SE
Prague,
Czech Republic
|
+$308K |
| 2 |
Aberdeen Group
Edinburgh,
United Kingdom
|
+$217K |
| 3 |
Renaissance Technologies
New York
|
+$198K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$174K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$153K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$6.15M |
| 2 |
SVCM
Saturn V Capital Management
Austin,
Texas
|
-$1.21M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$895K |
| 4 |
Millennium Management
New York
|
-$884K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$606K |
INZY Hedge Fund Activity: Q1 2025 in Review
97 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Inozyme Pharma (INZY) for Q1 2025, worth a combined $42.5M — down 71% from $145M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of INZY and 12 opened new positions — a net loss of 8 holders — while 29 trimmed existing stakes and 30 added.
The largest buyer was Pale Fire Capital SE, adding an estimated $308K. The largest seller was Eventide Asset Management, exiting entirely with an estimated $6.15M sold.
- 97 institutional investors held Inozyme Pharma (INZY) as of Q1 2025, down from 105 in Q4 2024.
- Funds reported $42.5M of Inozyme Pharma stock for Q1 2025, down 71% quarter-over-quarter.
- 12 funds opened new Inozyme Pharma positions in Q1 2025 and 20 closed out, a net change of -8 holders.
- The largest Inozyme Pharma buyer in Q1 2025 was Pale Fire Capital SE, an estimated $308K added.
- The largest Inozyme Pharma seller in Q1 2025 was Eventide Asset Management, an estimated $6.15M sold.
Based on aggregated 13F filings for Q1 2025.